Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

Completion of Strategic Acquisition Reflected in Q3 Results

FRANKLIN, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE) today announced financial results for the third quarter ended September 30, 2007. For the quarter ended September 30, 2007, net loss was $8,677,000 or $.70 per share, compared to $1,390,000 or $.49 per share, for the same period in 2006. For the nine months ended September 30, 2007, net loss was $10,278,000, or $1.05 per share, compared to $4,229,000 or $1.60 per share, for the same period in 2006. Net loss for the three and nine months ended September 30, 2007 included purchased research and development of $6,556,000 in connection with the strategic acquisition of Echo Therapeutics, Inc. as described in more detail below.

Cash and short term investments totaled $2,218,000 at September 30, 2007, compared to $559,000 at December 31, 2006.

Recent Highlights

The quarter was highlighted by the merger of Sontra Medical Corporation with Echo Therapeutics, Inc. and the surviving Company's name change to Echo Therapeutics, Inc. The merger created a dual platform-enabled transdermal therapeutics and diagnostics company focused on multiple large markets for improved formulations of specialty pharmaceuticals and new applications of next generation transdermal diagnostics for diabetes management and hospital intensive care markets. Echo Therapeutics is now marked by the following key attributes and capabilities:

-- Two transdermal drug penetration technologies, with emphasis on

development and commercialization advanced reformulations of

well-established, FDA-approved products using Echo's AzoneTS dermal

penetration enhancement technology in concert with a 505(b)(2)

regulatory strategy and development of a next generation wireless,

needle-free, continuous transdermal glucose monitor system for the

diabetes home use an
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and Markets ( ... new report "Gene Therapy - Technologies, Markets and ... for gene therapy are difficult to estimate as there ... is marketed in China since ... 2014-2024. The estimates are based on epidemiology of diseases ...
(Date:9/2/2015)... CUMBERLAND, R.I. , Sept. 2, 2015 /PRNewswire/ ... has been enrolled in the multicenter Phase 2 ... for the long-term treatment of recurrent subfoveal choroidal ... AMD).  NT-503 is a unique vascular endothelial growth ... versatile ECT implant. "This landmark proof-of-concept ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... will be attending Pharma Ed Resources upcoming educational seminar and training session ... leading speakers, this timely conference will provide Updates & Case Studies on the ...
Breaking Biology Technology:Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... Up, Net Loss Down, Cash Position Strong, as Pipeline ... Continues to ... EXEL ) today reported financial results for the full,year and fourth quarter ... compared to $98.7 million in,2006. The increase in revenues for the full ...
... Revenue Increased 69.8% to $7.7 million ... - Second Quarter Net Income Increased 67.5% to $1.7 million, - First Six Months Revenues ... Increased 65% to $3.2 million for the Same Period, - Growth Driven ... ...
... Afford Life-Saving Biopharmaceuticals, WASHINGTON, Feb. 14 ... legislation that would create a pathway for,FDA approval ... new print,advertisement that features a footprint in the ... The ad highlights how meaningful biogenerics legislation ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 2Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 3Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 4Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 5Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 6Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 7Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results 8
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... new sales campaign for Q4 2015. The new marketing ... team consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) ... Group is a leader in retail driven marketing and ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... recognized leader in the emerging field of systems biology whose ... birth defects, has been named the Donald Bren Professor of ... Professors Endowment was established with a gift from Donald Bren, ... and retain the nation,s foremost scholars. Lander joins a distinguished ...
... large cats faced with relentless human encroachment will seek ... swamp forests. These harsh coastal biomes are characterized by ... and poor soil in the form of highly ... decomposed leaves and wood. As such, swamp forests are ...
... available in German . , On the ... the Karlsruher Institut fr Technologie, or KIT for short, in ... has realized another important milestone: the second process stage of ... high-pressure entrained flow gasifier bioliq II was handed over for ...
Cached Biology News:Developmental biologist Arthur Lander named Donald Bren Professor 2Where the wild things go… when there's nowhere else 2Bioliq pilot plant: Successful operation of high-pressure entrained flow gasification 2Bioliq pilot plant: Successful operation of high-pressure entrained flow gasification 3
BD BioCoat Laminin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
BD BioCoat Collagen I 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of rat tail collagen type I....
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (C6671) or ... tissue-culture treated yes Surface area 148 ...
... This CLS number is a new ... product number. If showing no availability yet, ... (Z71,371-6) or contact customer service for assistance. ... Comp Dim: surface area 500 cm ...
Biology Products: